Home › Funds › Rhenman & Partners Asset Management AB › PRCT

Rhenman & Partners Asset Management AB position in PRCT

PROCEPT BIOROBOTICS CORP · Health Care

Rhenman & Partners Asset Management AB reported holding 535,000 shares of PRCT (PROCEPT BIOROBOTICS CORP) in its Q3 2026 13F filing — a position valued at US$9.7M, representing 1.08% of its reported portfolio and ranking #39 among its reported holdings. Rhenman & Partners Asset Management AB has disclosed PRCT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)535.00K sh
Reported value held$9.75M
Portfolio Weight1.08%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Rhenman & Partners Asset Management AB's PRCT position evolved

Rhenman & Partners Asset Management AB first disclosed a stake in PRCT in Q3 2023 at 493,000 shares (US$16.2M). The position peaked in Q3 2024 at 445,000 shares, worth US$35.7M. Across 13 filings, Rhenman & Partners Asset Management AB increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 535,000 shares valued at US$9.7M — an increase of 190,000 shares quarter over quarter.. Notable position changes include a 57% increase in Q1 2024 (shares rose 24% over the following quarter), a 58% trim in Q2 2025 (shares fell 38% over the following quarter), a 105% increase in Q3 2025 (shares fell 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 493.00K $16.18M New
Q4 2023 310.00K $12.99M Reduce
Q1 2024 487.06K $24.07M Add
Q2 2024 440.00K $26.88M Reduce
Q3 2024 445.00K $35.65M Add
Q4 2024 420.35K $33.85M Reduce
Q1 2025 448.00K $26.10M Add
Q2 2025 190.00K $10.94M Reduce
Q3 2025 390.00K $13.92M Add
Q4 2025 611.00K $19.22M Add
Q1 2026 475.00K $11.88M Reduce
Q2 2026 345.00K $7.79M Reduce
Q3 2026 535.00K $9.75M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PRCT and 13F data

PRCT (PROCEPT BIOROBOTICS CORP) is a Health Care company. 17 other funds we track also report a position in PRCT — the largest reported positions include Soleus Capital Management, L.P. (US$22.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PRCT

All PRCT fund holders →

FAQ

How long has Rhenman & Partners Asset Management AB held PRCT?

Rhenman & Partners Asset Management AB has disclosed PRCT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Rhenman & Partners Asset Management AB's current position in PRCT?

As of Q3 2026, Rhenman & Partners Asset Management AB holds 535.00K shares of PRCT (PROCEPT BIOROBOTICS CORP), valued at $9.75M, representing 1.08% of its reported portfolio and ranking #39.

Has Rhenman & Partners Asset Management AB been buying or selling PRCT?

In the latest 13F filing (Q3 2026), Rhenman & Partners Asset Management AB increased its position in PRCT. The position peaked in Q3 2024 at 445.00K shares.

Which other funds hold PRCT?

Other major institutional holders of PRCT include Soleus Capital Management, L.P., among 17 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.